ACADIA Pharmaceuticals Inc. (ACAD)

47.93
3.47 6.75
NASDAQ : Health Technology
Prev Close 51.40
Open 51.13
Day Low/High 47.88 / 51.40
52 Wk Low/High 14.01 / 53.70
Volume 1.70M
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 154.03M
Market Cap 7.78B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

The Good, the Bad and the Ugly (2:30 PM Edition)

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Acadia upgraded at BofA/Merrill

My Takeaways and Observations (Early Edition)

I have been warning about weakening breadth and narrow leadership for weeks and months.   What have we gotten? Eight straight days (in a row) down for the first time since 2008.   But, with stocks suffering from election uncertainties and given the ...

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

Main Biotech Indices Surrender Yesterday's Gains

It was good to stand in for Doug Kass today. Lots of lively conversation this Friday (over 200 comments), most of them around the markets as well....:-). The Daily Diary was certainly more interesting than today's market, which ended mixed as it clo...

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

The Good, the Bad and the Ugly

"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today.   Markets were higher from the get-go and seemed "stuck" nea...

My Takeaways and Observations

It was a nostalgic morning. A 20th anniversary.  My first TST column in 1997.  There was no rest for the weary as the crude and oil markets turned on a dime after OPEC announced a production cut. I, Jim Cramer and others are skeptical about this - s...

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Bret Jensen Reporting for Duty

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...

Tracking Bullish and Bearish Reversals

Tracking Bullish and Bearish Reversals

These stocks have made U-turns in the past week.

Biowreck!

I warned in yesterday's Good, Bad and Ugly against taking shots on speculative stocks like biotech. Well, the biotech space is getting pummeled today. For example, Sage Therapeutics is down 11.8% as I write this, while Acadia Pharmaceuticals is off ...

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Acadia downgraded at BofA/Merrill

My Takeaways and Observations

Buyers live higher, sellers live lower. Markets are still Fed-centric and governed by the last lean by Yellen. Ali Ali Ali!  Here's a very good column from El Capitan.   Apple (AAPL) is Crapple (Part Deux)  Fastenal (FAST) is always a good proxy for...

4 Possible Acquisition Targets in Biotech

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

My Takeaways and Observations

I started the day with an updated and still ursine market update: "Hey, Let's Be Careful Out There."   A new investment short -- England, via iShares MSCI United Kingdom (EWU).  EWU as a short went on my Best Ideas List. Jim Chanos and I are thinkin...

Acadia downgraded at Leerink

4 Possible Biotech M&A Targets

4 Possible Biotech M&A Targets

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.

My Takeaways and Observations

Today and yesterday are good examples of the fondness of crowds, and that buyers live higher and sellers live lower. Stocks closed at the day's highs, despite a reversal in the price of crude oil and some weak domestic data and disappointing retail ...

My Takeaways and Observations

Another strong market day.  The issue of taxes was front and center today. Here are some of my takes: My Take on Corporate Taxes  Man Up, Allergan Shareholders  Who Loses in Pfizer/Allergan Deal's Demise?  I remain manifestly bearish, in the belief ...

Today's Takeaways and Observations (Early Edition)

I started the day today by dissing the banks.                  Then, I unfriended Facebook (FB) by making it my Short Trade of the Week. Finally, I offered another critical post about auto stocks. Hey, at least I'm consistent! And at least I like Op...

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

My Takeaways and Observations

Take this, bulls!  This, too!  I ended the day with my highest net short exposure in more than 12 months. Committed in view, or to be committed? You decide. The U.S. dollar declined in value today. This seems to be a key element of the bulls' argume...

U.S. Futures Have Strong Start to Week

U.S. Futures Have Strong Start to Week

U.S. futures are climbing Monday after major indices experienced a dip in trading last week.